Search Results 1271-1280 of 11396 for anti-TNF drugs

  1. Clinical trials - Oncology (Medical)

    1) in patients with relapsed and/or refractory diffuse large B cell lymphoma (DLBCL) after receiving at least two lines of therapy. Additional cohorts include ...

  2. IL-2 Plus FOLFOX And Nivolumab For Treatment Of Peritoneal Metastases - Mayo Clinic

    The purpose of this study is to evaluate the reduction in the peritoneal carcinomatosis index (PCI) after completion of the study treatment. Participation ...

  3. Neurofibromatosis type 1 - Diagnosis and treatment - Mayo Clinic

    Many complications of NF1 can be treated effectively if therapy starts early. Medications. Medicines have been approved by the U.S. Food and Drug Administration ...

  4. Peripheral nerve tumors - Doctors and departments - Mayo Clinic

    Learn about these growths that form in or near nerves connecting to the spinal cord. Surgery is the most common treatment.

  5. Mayo Clinic study suggests which glioblastoma patients may benefit from drug treatment

    JACKSONVILLE, Fla. — Clinicians testing the drug dasatinib, approved for several blood cancers, had hoped it would slow the aggressive growth of the deadly ...

  6. Colon Melanoma Clinical Trials

    ... anti-PD-[L]-1 therapy. Nab-Paclitaxel and Bevacizumab in Treating Patients ... Drugs used in chemotherapy, such as paclitaxel albumin-stabilized ...

  7. Study Of Efficacy And Safety Of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With Or Without Ribavirin For Participants With Hepatitis C Genotype 1, 4, Or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068) - Mayo Clinic

    By condition, treatment or drug name ... anti-HCV antibody, HCV RNA, or any of the listed ... (TNF) antagonists, or other immunosuppressant drugs during the course ...

  8. Clinical trials - Oncology (Medical)

    Venetoclax is FDA approved for the treatment of CLL and SLL. The drug combination of acalabrutinib, durvalumab, and venetoclax is experimental and isn't ...

  9. Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma - Mayo Clinic

    Rituximab, an anti-CD20 chimeric antibody, was approved by the United States Food and Drug Administration in 1998 for the treatment of patients with relapsed ...

  10. Ramucirumab Plus Pembrolizumab Vs Usual Care For Treatment Of Stage IV Or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study - Mayo Clinic

    Ramucirumab Plus Pembrolizumab Vs Usual Care For Treatment Of Stage IV Or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study.